|
CALCIUM CHANNEL BLOCKERS TEND TO PRODUCE HYPERGLYCEMIA LEADING TO LOSS OF DIABETES CONTROL
|
POSSIBLE POTENTIATION OF BRADYCARDIA, SINUS ARREST AND AV BLOCK
|
ANTACIDS CAN DELAY & DECREASE ABSORPTION
|
ANTACIDS CAN DELAY & DECREASE ABSORPTION
|
ANTACIDS CAN DELAY & DECREASE ABSORPTION
|
ANTACIDS CAN DELAY & DECREASE ABSORPTION
|
ANTACIDS CAN DELAY & DECREASE ABSORPTION
|
ANTACIDS CAN DELAY & DECREASE ABSORPTION
|
ANTACIDS CAN DELAY & DECREASE ABSORPTION
|
INCREASED RISK OF MYOCARDIAL DEPRESSION
|
AMPHETAMINE MAY REDUCE THE HYPOTENSIVE EFFECTS OF ANTIHYPERTENSIVES INCLUDING BETABLOCKERS
|
AMPHETAMINE MAY REDUCE THE HYPOTENSIVE EFFECTS OF ANTIHYPERTENSIVES INCLUDING BETABLOCKERS
|
AMPHETAMINE MAY REDUCE THE HYPOTENSIVE EFFECTS OF ANTIHYPERTENSIVES INCLUDING BETABLOCKERS
|
AMPHETAMINE MAY REDUCE THE HYPOTENSIVE EFFECTS OF ANTIHYPERTENSIVES INCLUDING BETABLOCKERS
|
CALCIUM CHANNEL BLOCKER MAY ALSO HAVE AN ADDITIVE EFFECT & INCREASE THE LIKELIHOOD OF CHF, SEVERE HYPOTENSION & EXACERBATION OF ANGINA WHEN USED WITH ATENOLOL OR OTHER BETABLOCKERS
|
CALCIUM CHANNEL BLOCKER MAY ALSO HAVE AN ADDITIVE EFFECT & INCREASE THE LIKELIHOOD OF CHF, SEVERE HYPOTENSION & EXACERBATION OF ANGINA WHEN USED WITH ATENOLOL OR OTHER BETABLOCKERS
|
CALCIUM CHANNEL BLOCKER MAY ALSO HAVE AN ADDITIVE EFFECT & INCREASE THE LIKELIHOOD OF CHF, SEVERE HYPOTENSION & EXACERBATION OF ANGINA WHEN USED WITH ATENOLOL OR OTHER BETABLOCKERS
|
CALCIUM CHANNEL BLOCKER MAY ALSO HAVE AN ADDITIVE EFFECT & INCREASE THE LIKELIHOOD OF CHF, SEVERE HYPOTENSION & EXACERBATION OF ANGINA WHEN USED WITH ATENOLOL OR OTHER BETABLOCKERS
|
CALCIUM CHANNEL BLOCKER MAY ALSO HAVE AN ADDITIVE EFFECT & INCREASE THE LIKELIHOOD OF CHF, SEVERE HYPOTENSION & EXACERBATION OF ANGINA WHEN USED WITH ATENOLOL OR OTHER BETABLOCKERS
|
CALCIUM CHANNEL BLOCKER MAY ALSO HAVE AN ADDITIVE EFFECT & INCREASE THE LIKELIHOOD OF CHF, SEVERE HYPOTENSION & EXACERBATION OF ANGINA WHEN USED WITH ATENOLOL OR OTHER BETABLOCKERS
|
CALCIUM CHANNEL BLOCKER MAY ALSO HAVE AN ADDITIVE EFFECT & INCREASE THE LIKELIHOOD OF CHF, SEVERE HYPOTENSION & EXACERBATION OF ANGINA WHEN USED WITH ATENOLOL OR OTHER BETABLOCKERS
|
CALCIUM CHANNEL BLOCKER MAY ALSO HAVE AN ADDITIVE EFFECT & INCREASE THE LIKELIHOOD OF CHF, SEVERE HYPOTENSION & EXACERBATION OF ANGINA WHEN USED WITH ATENOLOL OR OTHER BETABLOCKERS
|
CALCIUM CHANNEL BLOCKER MAY ALSO HAVE AN ADDITIVE EFFECT & INCREASE THE LIKELIHOOD OF CHF, SEVERE HYPOTENSION & EXACERBATION OF ANGINA WHEN USED WITH ATENOLOL OR OTHER BETABLOCKERS
|
CALCIUM CHANNEL BLOCKER MAY ALSO HAVE AN ADDITIVE EFFECT & INCREASE THE LIKELIHOOD OF CHF, SEVERE HYPOTENSION & EXACERBATION OF ANGINA WHEN USED WITH ATENOLOL OR OTHER BETABLOCKERS
|
CALCIUM CHANNEL BLOCKER MAY ALSO HAVE AN ADDITIVE EFFECT & INCREASE THE LIKELIHOOD OF CHF, SEVERE HYPOTENSION & EXACERBATION OF ANGINA WHEN USED WITH ATENOLOL OR OTHER BETABLOCKERS
|
CALCIUM CHANNEL BLOCKER MAY ALSO HAVE AN ADDITIVE EFFECT & INCREASE THE LIKELIHOOD OF CHF, SEVERE HYPOTENSION & EXACERBATION OF ANGINA WHEN USED WITH ATENOLOL OR OTHER BETABLOCKERS
|
CALCIUM CHANNEL BLOCKER MAY ALSO HAVE AN ADDITIVE EFFECT & INCREASE THE LIKELIHOOD OF CHF, SEVERE HYPOTENSION & EXACERBATION OF ANGINA WHEN USED WITH ATENOLOL OR OTHER BETABLOCKERS
|
CALCIUM CHANNEL BLOCKER MAY ALSO HAVE AN ADDITIVE EFFECT & INCREASE THE LIKELIHOOD OF CHF, SEVERE HYPOTENSION & EXACERBATION OF ANGINA WHEN USED WITH ATENOLOL OR OTHER BETABLOCKERS
|
CALCIUM CHANNEL BLOCKER MAY ALSO HAVE AN ADDITIVE EFFECT & INCREASE THE LIKELIHOOD OF CHF, SEVERE HYPOTENSION & EXACERBATION OF ANGINA WHEN USED WITH ATENOLOL OR OTHER BETABLOCKERS
|
CALCIUM CHANNEL BLOCKER MAY ALSO HAVE AN ADDITIVE EFFECT & INCREASE THE LIKELIHOOD OF CHF, SEVERE HYPOTENSION & EXACERBATION OF ANGINA WHEN USED WITH ATENOLOL OR OTHER BETABLOCKERS
|
CALCIUM CHANNEL BLOCKER MAY ALSO HAVE AN ADDITIVE EFFECT & INCREASE THE LIKELIHOOD OF CHF, SEVERE HYPOTENSION & EXACERBATION OF ANGINA WHEN USED WITH ATENOLOL OR OTHER BETABLOCKERS
|
CALCIUM CHANNEL BLOCKER MAY ALSO HAVE AN ADDITIVE EFFECT & INCREASE THE LIKELIHOOD OF CHF, SEVERE HYPOTENSION & EXACERBATION OF ANGINA WHEN USED WITH ATENOLOL OR OTHER BETABLOCKERS
|
CALCIUM CHANNEL BLOCKER MAY ALSO HAVE AN ADDITIVE EFFECT & INCREASE THE LIKELIHOOD OF CHF, SEVERE HYPOTENSION & EXACERBATION OF ANGINA WHEN USED WITH ATENOLOL OR OTHER BETABLOCKERS
|
CONCURRENT ADMINISTRATION MAY CAUSE BRADYCARDIA, MYOCARDIAL DEPRESSION OR A.V. BLOCK
|
CONCURRENT ADMINISTRATION MAY CAUSE BRADYCARDIA, MYOCARDIAL DEPRESSION OR A.V. BLOCK
|
CONCURRENT ADMINISTRATION MAY CAUSE BRADYCARDIA, MYOCARDIAL DEPRESSION OR A.V. BLOCK
|
CONCURRENT ADMINISTRATION MAY CAUSE BRADYCARDIA, MYOCARDIAL DEPRESSION OR A.V. BLOCK
|
CONCURRENT ADMINISTRATION MAY CAUSE BRADYCARDIA, MYOCARDIAL DEPRESSION OR A.V. BLOCK
|
CONCURRENT ADMINISTRATION MAY CAUSE BRADYCARDIA, MYOCARDIAL DEPRESSION OR A.V. BLOCK
|
CONCURRENT ADMINISTRATION MAY CAUSE BRADYCARDIA, MYOCARDIAL DEPRESSION OR A.V. BLOCK
|
CONCURRENT ADMINISTRATION MAY CAUSE BRADYCARDIA, MYOCARDIAL DEPRESSION OR A.V. BLOCK
|
CONCURRENT ADMINISTRATION MAY CAUSE BRADYCARDIA, MYOCARDIAL DEPRESSION OR A.V. BLOCK
|
CONCURRENT ADMINISTRATION MAY CAUSE BRADYCARDIA, MYOCARDIAL DEPRESSION OR A.V. BLOCK
|
CONCURRENT ADMINISTRATION MAY CAUSE BRADYCARDIA, MYOCARDIAL DEPRESSION OR A.V. BLOCK
|
CONCURRENT ADMINISTRATION MAY CAUSE BRADYCARDIA, MYOCARDIAL DEPRESSION OR A.V. BLOCK
|
CONCURRENT ADMINISTRATION MAY CAUSE BRADYCARDIA, MYOCARDIAL DEPRESSION OR A.V. BLOCK
|
CONCURRENT ADMINISTRATION MAY CAUSE BRADYCARDIA, MYOCARDIAL DEPRESSION OR A.V. BLOCK
|
CONCURRENT ADMINISTRATION MAY CAUSE BRADYCARDIA, MYOCARDIAL DEPRESSION OR A.V. BLOCK
|
CONCOMITANT USE MAY CAUSE SEVERE CARDIAC ARRHYTHMIAS
|
INCREASED HYPOTENSIVE EFFECT IS SEEN
|
INCREASED HYPOTENSIVE EFFECT IS SEEN
|
INCREASED HYPOTENSIVE EFFECT IS SEEN
|
INCREASED HYPOTENSIVE EFFECT IS SEEN
|
INCREASED HYPOTENSIVE EFFECT IS SEEN
|
INCREASED HYPOTENSIVE EFFECT IS SEEN
|
INCREASED HYPOTENSIVE EFFECT IS SEEN
|
INCREASED HYPOTENSIVE EFFECT IS SEEN
|
INCREASED HYPOTENSIVE EFFECT IS SEEN
|
INCREASED HYPOTENSIVE EFFECT IS SEEN
|
INCREASED HYPOTENSIVE EFFECT IS SEEN
|
INCREASED HYPOTENSIVE EFFECT IS SEEN
|
INCREASED HYPOTENSIVE EFFECT IS SEEN
|
INCREASED HYPOTENSIVE EFFECT IS SEEN
|
INCREASED HYPOTENSIVE EFFECT IS SEEN
|
H-2 RECEPTOR ANTAGONIST LIKE CIMETIDINE MAY INCREASE ITS SERUM CONCENTRATION
|
CO-ADMINISTRATION MAY POTENTIATE HYPERTENSIVE EFFECT OF THE DRUG
|
CO-ADMINISTRATION OF DIGOXIN AND CALCIUM CHANNEL BLOCKERS MAY RESULT IN THE ADDITIVE EFFECTS ON AV NODE CONDUCTION
|
CO-ADMINISTRATION OF DIGOXIN AND CALCIUM CHANNEL BLOCKERS MAY RESULT IN THE ADDITIVE EFFECTS ON AV NODE CONDUCTION
|
KETOCONAZOLE MAY INCREASE THE PLASMA LEVELS OF THE DRUG
|
KETOCONAZOLE MAY INCREASE THE PLASMA LEVELS OF THE DRUG
|
KETOCONAZOLE MAY INCREASE THE PLASMA LEVELS OF THE DRUG
|
KETOCONAZOLE MAY INCREASE THE PLASMA LEVELS OF THE DRUG
|
CALCIUM CHANNEL BLOCKERS POTENTIATE THE DEPRESSION OF CARDIAC CONTRACTILITY, CONDUCTIVITY, AND AUTOMATICITY AS WELL AS VASCULAR DILATION ASSOCIATED WITH ANESTHETICS
|
CALCIUM CHANNEL BLOCKERS POTENTIATE THE DEPRESSION OF CARDIAC CONTRACTILITY, CONDUCTIVITY, AND AUTOMATICITY AS WELL AS VASCULAR DILATION ASSOCIATED WITH ANESTHETICS
|
CO-ADMINISTRATION MAY RESULT IN INCREASED HYPOTENSIVE EFFECT
|
RIFAMPICIN MAY ACCELERATES METABOLISM OF THE DRUG & MAY CAUSE DECREASED PLASMA CONCENTRATION
|
PHENOBARBITONE ENHANCES DRUG METABOLISM HENCE DECREASED SERUM LEVELS OF THE DRUG HAVE BEEN OBSERVED
|
PHENOBARBITONE ENHANCES DRUG METABOLISM HENCE DECREASED SERUM LEVELS OF THE DRUG HAVE BEEN OBSERVED
|
PHENOBARBITONE ENHANCES DRUG METABOLISM HENCE DECREASED SERUM LEVELS OF THE DRUG HAVE BEEN OBSERVED
|
PHENOBARBITONE ENHANCES DRUG METABOLISM HENCE DECREASED SERUM LEVELS OF THE DRUG HAVE BEEN OBSERVED
|
PHENOBARBITONE ENHANCES DRUG METABOLISM HENCE DECREASED SERUM LEVELS OF THE DRUG HAVE BEEN OBSERVED
|
PHENOBARBITONE ENHANCES DRUG METABOLISM HENCE DECREASED SERUM LEVELS OF THE DRUG HAVE BEEN OBSERVED
|
BENZODIAZEPINES / DIAZEPAM CLEARANCE IS REDUCED BY CO-ADMINISTRATION; HENCE THE DOSE OF DIAZEPAM IS REDUCED BY ONE THIRD
|
BENZODIAZEPINES / DIAZEPAM CLEARANCE IS REDUCED BY CO-ADMINISTRATION; HENCE THE DOSE OF DIAZEPAM IS REDUCED BY ONE THIRD
|
BENZODIAZEPINES / DIAZEPAM CLEARANCE IS REDUCED BY CO-ADMINISTRATION; HENCE THE DOSE OF DIAZEPAM IS REDUCED BY ONE THIRD
|
BENZODIAZEPINES / DIAZEPAM CLEARANCE IS REDUCED BY CO-ADMINISTRATION; HENCE THE DOSE OF DIAZEPAM IS REDUCED BY ONE THIRD
|
BENZODIAZEPINES / DIAZEPAM CLEARANCE IS REDUCED BY CO-ADMINISTRATION; HENCE THE DOSE OF DIAZEPAM IS REDUCED BY ONE THIRD
|
BENZODIAZEPINES / DIAZEPAM CLEARANCE IS REDUCED BY CO-ADMINISTRATION; HENCE THE DOSE OF DIAZEPAM IS REDUCED BY ONE THIRD
|
BENZODIAZEPINES / DIAZEPAM CLEARANCE IS REDUCED BY CO-ADMINISTRATION; HENCE THE DOSE OF DIAZEPAM IS REDUCED BY ONE THIRD
|
BENZODIAZEPINES / DIAZEPAM CLEARANCE IS REDUCED BY CO-ADMINISTRATION; HENCE THE DOSE OF DIAZEPAM IS REDUCED BY ONE THIRD
|
BENZODIAZEPINES / DIAZEPAM CLEARANCE IS REDUCED BY CO-ADMINISTRATION; HENCE THE DOSE OF DIAZEPAM IS REDUCED BY ONE THIRD
|
BENZODIAZEPINES / DIAZEPAM CLEARANCE IS REDUCED BY CO-ADMINISTRATION; HENCE THE DOSE OF DIAZEPAM IS REDUCED BY ONE THIRD
|
BENZODIAZEPINES / DIAZEPAM CLEARANCE IS REDUCED BY CO-ADMINISTRATION; HENCE THE DOSE OF DIAZEPAM IS REDUCED BY ONE THIRD
|
BENZODIAZEPINES / DIAZEPAM CLEARANCE IS REDUCED BY CO-ADMINISTRATION; HENCE THE DOSE OF DIAZEPAM IS REDUCED BY ONE THIRD
|
BENZODIAZEPINES / DIAZEPAM CLEARANCE IS REDUCED BY CO-ADMINISTRATION; HENCE THE DOSE OF DIAZEPAM IS REDUCED BY ONE THIRD
|
BENZODIAZEPINES / DIAZEPAM CLEARANCE IS REDUCED BY CO-ADMINISTRATION; HENCE THE DOSE OF DIAZEPAM IS REDUCED BY ONE THIRD
|
BENZODIAZEPINES / DIAZEPAM CLEARANCE IS REDUCED BY CO-ADMINISTRATION; HENCE THE DOSE OF DIAZEPAM IS REDUCED BY ONE THIRD
|
BENZODIAZEPINES / DIAZEPAM CLEARANCE IS REDUCED BY CO-ADMINISTRATION; HENCE THE DOSE OF DIAZEPAM IS REDUCED BY ONE THIRD
|
FRUSEMIDE MAY ADD TO OR POTENTIATE THE THERAPEUTIC OF OTHER ANTIHYPERTENSIVE DRUGS
|
FRUSEMIDE MAY ADD TO OR POTENTIATE THE THERAPEUTIC OF OTHER ANTIHYPERTENSIVE DRUGS
|